PHI prostate health index
Selected indexed studies
- Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis. (Clin Chem Lab Med, 2022) [PMID:35567430]
- Prostate health index (PHI) as an accurate prostate cancer predictor. (J Cancer Res Clin Oncol, 2023) [PMID:37204514]
- Beyond PSA: The Role of Prostate Health Index (phi). (Int J Mol Sci, 2020) [PMID:32053990]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis. (2022) pubmed
- Prostate health index (PHI) as an accurate prostate cancer predictor. (2023) pubmed
- Beyond PSA: The Role of Prostate Health Index (phi). (2020) pubmed
- Role of prostate health index (PHI) in prostate cancer screening: cost minimization analysis through simulation modelling. (2025) pubmed
- Prostate Cancer. (2026) pubmed
- Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection. (2022) pubmed
- Measurement Uncertainty and the Prostate Health Index-A Review. (2025) pubmed
- Prostate Health Index (PHI) as a triage tool for reducing unnecessary magnetic resonance imaging (MRI) in patients at risk of prostate cancer. (2024) pubmed
- Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. (2013) pubmed
- The prostate health index (PHI) density: Are there advantages over PHI or over the prostate-specific antigen density? (2021) pubmed